In this paper, we describe the application of an integrated electromechanics-growth computational model to simulate the long term effects of cardiac regenerative therapies in a left ventricle (LV). The electromechanics-growth model couples biophysically detailed cellular-based laws that describe the short term events occurring in the excitation-contraction coupling process in the cardiomyocytes, to a phenomenological law that describes the long-term process of growth and remodeling in the cardiac tissue. Two clinically relevant phases depicting the progression and subsequent treatment of heart failure were simulated using this model. These phases are namely, (1) the long-term remodeling process induced by a myocardial infarction and (2) the long-term response following regeneration of the infarct. Our model predictions show that the abnormal myofi ber strain values surrounding the infarct can drive the post-infarct LV hypertrophy, whereas a subsequent normalization of the myofi ber strain after infarct regeneration can lead to a reduction in the LV size. These fi ndings are consistent with some of the observations found in the experiments and clinical studies of cardiac regenerative therapies.
INTRODUCTION
Heart failure (HF) continues to pose a signifi cant burden on our society. Between 2010 and 2030, the real cost of HF is projected to increase by a staggering 200% 1 . Among all HF conditions, 70% of them are of systolic origin with coronary artery diseases accounting for approximately twothirds of these cases 2 . In the event of myocardial infarction (MI) in adult mammals, cardiomyocytes, unlike other cells, do not regenerate suffi ciently to replace the lost ones. Th e end result of this is a permanent loss of contractile function in the infarcted region.
Current standard therapy for treating MI includes pharmacological treatments such as the admininstration of thrombolytic agents to restore coronary blood fl ow, and angiotensin-converting enzyme inhibitors to reduce blood pressure 3 . Th e long-term prognosis of MI remains poor. Although current treatments have improved MI survival signifi cantly, around 24% of MI survivors still progress on to develop HF which has limited treatment options 4 . To address this issue, a myriad of new devices and treatments for MI have been developed in recent years, e.g. surgical ventricular restoration 5 , ventricular partitioning device 6 and cardiac regenerative therapies 7, 8 . Among these treatments, cell-based cardiac regenerative therapies have recently garnered a considerable interest. Multiple strategies are currently under investigation to regenerate diseased hearts. Th ese strategies include the direct transplantation of stem cells into the infarcted myocardium, and the reprogramming of residing non-myocytes to cardiomyocytes in the diseased heart 7 . A number of clinical and experimental studies on these regenerative therapies have shown favorable post-treatment outcome in the form of an attenuation or a reversal of the adverse cardiac remodeling process 9, 10 . Th e same positive outcome is, however, not found in other studies 11 . A better understanding on the mechanisms of cardiac regenerative therapies is, therefore, very much needed before they can be optimally applied to treat MI.
Computational models have been developed over the years to study a number of heart disease treatments [12] [13] [14] [15] [16] [17] [18] [19] . While these models have been limited to simulating the immediate eff ects of the heart that results from a treatment, recent advancements in theory and model development have led to an emerging class of models that can describe the long term cardiac remodeling process [20] [21] [22] [23] [24] . A small number of these models have recently been used to evaluate the long-term eff ects of HF and treatments 24, 25 .
Here, we applied a recently developed electromechanics-growth model 26 to simulate the long-term effects of cardiac regenerative therapies. Th is growth model was established based on the principle that cardiomyocytes undergo hypertrophy or atrophy in order to restore strain INVITED ARTICLE homeostasis 23 . Simulations using this model have shown that the collective long-term behavior of cardiomyocytes in response to an elevated and a reduced global mechanical loading results in, respectively, the dilation and shrinkage of the left ventricle (LV). Th is feature has been observed in hearts implanted with a left ventricular assist device 27 . Although the growth model has been used to simulate the long-term behavior of an LV with a non-contractile infarct 26 , this model, however, has not been applied to simulate the case when the non-contractile infarct is regenerated and populated with contracting cardiomyocytes. By applying this model to simulate the fi rst order eff ects of cardiac regenerative therapies here, we seek to test whether our model prediction is consistent with observations in experiments and clinical studies. Doing so will also enable us to understand how the surviving cardiomyocytes in the non-infarcted region will respond collectively to a regional restoration of the infarct contractile function. Figure 1 shows a schematic of the electromechanics-growth model containing its key equations. Th e details of the model are given in Lee et al. 26 Here, we summarize the model with references to the equations given in the fi gure. Briefl y, the model is an integration of a cardiac growth constitutive model 23 with a cardiac electromechanics model 28 . Cardiac electrophysiology was described by the bidomain equations (Equations 1,2), where M i , M e , v and v e are, respectively, the intracellular, extracellular conductivity tensors (both scaled with the membrane capacitance and the cell membrane area to volume ratio), the transmembrane potential and the extracellular potential. A cellular electrophysiology model 29 was used to describe the exchange of ions across the cardiac cell membrane. Th is model was coupled to a cellular model describing the cross-bridge kinetics 30 via a vector of state variables s, consisting of various membrane channels and intracellular ionic concentrations (Equation 3 ).
METHODS

Electromechanics-growth model
An active stress formulation was used to describe the mechanics of the cardiac tissue. In this formulation, the Cauchy stress tensor σ was additively decomposed into an active component σ a and a passive component σ p . Th e active stress σ a was described by a cellular-based cross-bridge model 30 (Equation 5 ) that was scaled by a parameter T that refl ects the local tissue contractility. On the other hand, the passive stress σ p was described by a prescribed Fung-type strain energy function W 31 (Equation 6 ). Near incompressibility of the tissue was enforced by splitting the strain energy function into a deviatoric component and a dilational component, and prescribing a large bulk modulus in the latter 32 . Th e stress tensor σ has to satisfy the balance of linear momentum equation (Equation 4).
Equations (1) to (6) describe the short term electromechanical behavior of the heart during a cardiac cycle. The cardiac cycle was simulated by fi rst incrementally applying pressure to the LV endocardial surface until a prescribed end-diastolic pressure is reached. Systole was simulated by stimulating the LV apex. We note that this is a simplifi cation of normal activation in the LV, which in actuality occurs through the Purkinje fi ber system. Th e LV cavity volume was constrained to remain constant during the isovolumic contraction phase until the LV pressure reached the prescribed aortic valve opening pressure. Th ereaft er, the ejection phase was simulated by coupling the LV cavity volume to a three-parameter Windkessel model (Fig. 1) . Ejection ceased in the simulation when the LV volumetric fl ow rate becomes negative, and the LV cavity volume was constrained to remain constant during the subsequent isovolumic relaxation phase. Ventricular fi lling begin when the LV cavity pressure fell below a prescribed pressure and the cardiac cycle repeats itself.
To describe long-term cardiac growth, we used the theoretical volumetric-growth framework 33 in which the deformation gradient tensor F was multiplicatively decomposed into a growth tensor F g and an elastic deformation tensor F e (Equation 7). Th e growth tensor F g was parameterized by a growth multiplier θ so that growth and reverse growth occur only along the cardiomyocyte long axis (Equation 8). A constitutive relationship was prescribed for θ so that growth or reverse growth occur only if the myocyte stretch is greater or lesser than a prescribed homeostatic stretch values (Equation 9), respectively. Th is constitutive 34 , and (2) this behavior can be reversed upon removal of the overloading conditions 35, 36 . Because the cardiac growth model 23 and the electromechanics model 28 operate at two different timescales (i.e. growth and remodeling becomes appreciable only aft er a large number of heart beats), a separation of timescale was invoked to integrate the two models. Two assumptions are essential for separating the timescales. Th e fi rst assumption is that growth and remodeling occurs too slowly to be detectable on the timescale of a single heartbeat. Correspondingly, the growth tensor F g was assumed to be a constant within a cardiac cycle in our simulation. Th e second assumption is that the stimuli that drive growth and remodeling can be derived from a representative cardiac cycle. Th e simulation of a cardiac cycle then becomes equivalent to that of a "growth cycle" within which growth and remodeling is not detectable, and does not aff ect the electromechanics of the heart. By invoking these assumptions, the growth tensor was updated once every cardiac cycle at the end-of-diastole ( Fig. 1) . Specifi cally, the LV was unloaded at the end-of-diastole in each cycle and the updated growth tensor was then used to compute for the new "grown" unloaded geometry. Th ereaft er, the LV was loaded with the (same) prescribed end-diastolic pressure, and simulation of the cardiac cycle was resumed in the electromechanics model. Th is allows us to prescribe the time-averaged stretch over a cardiac cycle (or any other time-averaged quantities) as the growth stimulant for the cardiomyocytes 37 .
Left ventricular geometry
Th e electromechanics-growth model was applied to a human LV geometry that was reconstructed from magnetic resonance images 38 . Th ree distinct regions were prescribed in the LV, namely, the infarct, borderzone and remote (healthy) regions. Th ese regions diff ered from each other only in terms of the prescribed tissue contractility, a material parameter T (see Equation (5) in Fig. 1 that is denoted by the "reference tension" in the active contraction model 30 ). Th e infarct was assumed to be devoid of cardiomyocytes and, hence, was prescribed to be non-contractile and non-growing (i.e. T infarct = 0). Because cardiomyocytes taken from the borderzone were found in experiments (using direct active force measurements) to have reduced contractility when compared to those taken from the remote region 39 , the borderzone region was prescribed to have one-half the remote region's contractility in the simulation (i.e. T borderzone = 0.5 T normal ). Based on previous histological studies 40 , the helix angle that defi nes the cardiomyocytes long axis was prescribed to vary linearly across the myocardial wall from −60° (endocardium) to 60° (epicardium) in the entire LV (Fig. 2) . Local homeostatic timeaveraged stretch values λ -e of the cardiomyocytes were obtained in another simulation using the same LV geometry in which both the infarct and borderzone have contractilities equal to that in the remote region (i.e. the same LV but with homogeneous normal contractility T normal ). Standard fi nite element method was used to solve the LV model comprising of 4,425 linear tetrahedral elements (maximum element size = 0.3 cm). Because the focus here is on cardiac mechanics, the same mesh was used to discretize the electrophysiology bidomain equations (Equations 1,2 in Fig. 1 ) and the mechanical equlibrium equation (Equation 4 in Fig. 1) . We note that a fi ner mesh is required to yield accurate electrical wave propagation from the electrophysiology bidomain equations 41 . However, the current mesh is suffi cient to obtain numerical convergence for the mechanical equilibrium equation. In addition to this, we also did not observe any locking phenomena which tetrahedral elements are prone to when the material is nearly incompressible with a large bulk modulus. Timesteps ranging between 1 and 50 milliseconds were employed in the simulation, with the systolic phase simulated using a smaller timestep and the diastolic phase simulated using a larger timestep. Details and parameter values of the model can be found in Lee et al.
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Simulation protocol
To simulate the eff ects of introducing new contractile cardiomyocytes into the infarct in cardiac regenerative therapies, the following twophase simulation protocol was implemented. In the first phasethe remodeling phase, the LV model was ran for 5 growth cycles with impaired contractility in the infarct and the borderzone (i.e. T infarct = 0; T borderzone = 0.5 T normal ). Th e healthy remote region was prescribed with a normal contractility (i.e. T remote = T normal ). Th en, in the second phase -the post-treatment phase, the infarct and borderzone contractilities were restored back to the normal values (i.e. T infarct = T borderzone = T normal ) and the LV model was ran for another 10 growth cycles. Th e value of T normal was set to 60 kPa in the simulation. As a fi rst approximation, we prohibited the infarct from growing in the entire simulation, and so we did not account for any possible growth in the infarct caused by the newly introduced cardiomyocytes. Our simulation therefore only considers the eff ects of the new cardiomyocytes in restoring the infarct contractility, and how that in turn aff ects the residing cardiomyocytes.
RESULTS
Pressure-volume relationship
Our simulation results showed a right shift of the pressure-volume (PV) loop during the remodeling phase (fi rst fi ve cycles) when a non-contractile infarct and a borderzone with depressed contractility were present in the LV. Compared to the LV with normal contractile function that had an ejection fraction (EF) of 49% a , the infarcted LV showed a substantially smaller PV loop in the fi rst cycle (EF = 32%) that shift ed continuously towards the right in the next four cycles (EF at cycle 5 = 26%).
Restoration of the infarct and borderzone contractilities back to their normal values in the fi rst cycle of the post-treatment phase led to an a Note: the EF of 49% is slightly lower than the normal range of 55-70% that is typically found in normal humans. expected larger PV loop (EF = 47%). In subsequent cycles, the PV loop shift ed toward the left (Fig. 3b) and the EF was maintained.
Geometrical changes
Th e shift ing of PV loops was refl ected by a change in the LV geometry. During the remodeling phase, the LV became more dilated and spherical (Fig. 4a) . Growth in the LV occurred primarily in the borderzone as indicated by the larger values of the determinant of the growth tensor det F g found in that region. Th e larger values of det F g refl ects a lengthening of cardiomyocytes in the infarct borderzone.
During the post-treatment phase, the growth process was reversed and the LV became progressively smaller and more ellipsoidal (Fig. 4b) . Th e growth tensor's determinant det F g also decreased in the borderzone, refl ecting a shortening of cardiomyocytes in its longitudinal axis.
Myofi ber stretch
At the fi rst cycle of the remodeling phase (cycle 1), the time-averaged elastic myofi ber stretch λ -e was higher in both the infarct and borderzone when compared to that found in the same region in the normal LV (Fig. 5) . In subsequent cycles during this phase, however, the borderzone 
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elastic myofi ber stretch λ -e decreased and approached the values found in the normal LV. At the infarct, which was prescribed not to grow, the time-averaged elastic myofi ber stretch did not decrease but increased slightly during the remodeling phase. We note that the reason why λ -e was highest at the infarct is because the infarct did not contract but underwent stretching even during the systole phase in a cardiac cycle.
Contractility was restored in both the infarct and borderzone in the post-treatment phase. Th e immediate eff ect of this alteration (in cycle 6) was a reduction in the values of λ -e in these two regions. Th e reduced values were below the corresponding homeostatic values found in the normal LV. In subsequent cycles of the post-treatment phase, the timeaveraged elastic myofi ber stretch in the borderzone and infarct increased and approached their respective homeostatic values.
DISCUSSION
Although computational models have been used to simulate the longterm eff ects of heart diseases and therapies 25, 42, 43 , most models are only capable of simulating growth based on standard time points in the cardiac cycle (e.g. end-of-diastole or end-of-systole). As such, time-averaged, minima and maxima of local deformation signals cannot be applied as growth stimulant in these models, unless (of course), if these quantities are known a priori to correspond to particular time points in the cardiac cycle. Specifi c to volume overload where the cardiomyocytes elongates in its axial direction, an in vivo study on a rat model 37 suggests that the likely candidates for the hypertrophic stimuli are features of the time-varying volume signal, which are related to the myofi ber stretch or strain. Th ese features include the maximum, mean, amplitude, rates of rise and fall of the volume during the cardiac cycle. Additionally, in-vitro studies have also demonstrated that the hypertrophic gene expression is regulated by cyclic stretch of the cardiomyocytes 44, 45 . Motivated by these studies, we have used the time-averaged myofi ber stretch as the growth stimulant in our simulation. We have also, for the fi rst time, applied the electromechanics-growth model to simulate the long-term eff ects of cardiac regenerative therapies. Our simulation results show features that are generally consistent with experimental and clinical studies, both in the remodeling and post-treatment phases.
Remodeling phase
During the remodeling phase, our model predicts a higher time-averaged myofi ber stretch in both the borderzone and the infarct than that found in the normal LV (Fig. 5) . As a result, growth occurs primarily in the borderzone. Globally, this local growth causes the LV to become dilated and more spherical (Fig. 4) , which manifested as a shift ing of the PV loop toward the right (Fig. 3) .
All these features are consistent with experimental and clinical studies at the cellular and organ levels. First, abnormal stretch in the form of a reduced contractile deformation during systole is a widely observed feature found in the borderzone aft er MI 46, 47 . Correspondingly, cardiomyocytes in the borderzone region would, when averaged over a cardiac cycle, undergo higher stretching. Second, cardiomyocytes in the borderzone of animal MI models displayed appreciable hypertrophy when compared to those in remote region 39, 48 . For example, in the sheep heart, the cardiomyocytes' cross-sectional area was found to be about 70% higher than that in the remote region 2 weeks aft er MI 39 . Th e same observations were found in humans when isolated cardiomyocytes from explanted human hearts with ischemic-dilated cardiomyopathy were measured to be about 40% longer than those found in the normal heart 34 . Th ird, progressive LV dilation in the form of a parallel increase in both end-diastolic and end-systolic volumes is a pathophysiological feature of MI that is found in both humans and animals 49, 50 .
Post-treatment phase
Restoration of the infarct and borderzone contractilities to their normal values in our simulation led to an immediate increase in both stroke volume and EF. Th e time-averaged myofi ber stretch also decreased immediately and fell below its corresponding homeostatic values in the infarct and borderzone upon restoration of their contractilities (Fig. 5) . As a result, cardiomyocytes in the borderzone was predicted in our simulation to undergo atrophy Figure 5 Left: time-averaged myofi ber stretch λ -e in the infarct, borderzone and remote regions in the two simulation phases. Right: myofi ber stretch taken from arbitary locations in these regions (same color scheme applied here). Note that the infarct and borderzone were regenerated at the end of cycle 5.
which led to a reversal of growth during this post-treatment phase (Fig.  4) . Th is reversal was manifested globally by a decrease in the LV size that was refl ected by a continuous shift of the PV loop toward the left (Fig. 3) .
Cardiac regenerative therapies have, in recent years, garnered considerable interests. From the initial pilot studies on animal models where the results are mainly positive 9, 51, 52 , these therapies have progressed into clinical trials. Th e review by Pfi ster et al. 53 summarizes the fi ndings from the major recent clinical trials that investigate the use of diff erent types of stem cells, such as bone marrow, mesenchymal and resident cardiac stem cells. Th e results from these clinical trials are mixed and controversial, with some showing insignifi cant clinical effi ciacy [54] [55] [56] , while others showing significant functional improvments and reverse remodeling post-treatment [57] [58] [59] [60] . Clinical trials that found positive eff ects, including the POSEIDON study (mesenchymal stem cells) 58 and the SCIPO study (cardiac resident stem cells) 57 , have shown that the infarct size reduces signifi cantly (POSEIDON: 33%, SCIPO: 24-30%) at 4-12 months post-treatment. Th e signifi cant reduction in the infarct size in the SCIPO study was accompanied by an statistically signifi cant increase in EF by 8 pp., whereas the POSEIDON study found a 2 pp. increase in EF that is not statistically signifi cant. Th ese favorable eff ects were also found in another preclinical trial on the injection of mesenchymal and mononuclear stem cells 60 . In that study, a 20% decrease in infarct size, end-diastolic and end-systolic volumes, as well as a 4.5 pp. increase in EF were found aft er treatment. Our model, which of course is an idealization of these actual stem cell therapies, is able to replicate some of these fi ndings, which include an increase in EF as well as decreases in end-diastolic and end-systolic volumes.
Besides these global functional and geometrical changes, postmortem analysis in porcine hearts implanted with mesenchymal stem cell have also found that the cardiomyocytes in the sub-endocardial rim of the MI are not hypertrophied when compared to those taken from the remote region 61 . It is unclear, however, as to whether these unhypertrophied cardiomyocytes are proliferated endogeneous cardiomyocytes or newly diff erentiated ones. Similar fi ndings were also reported in rats treated with cardiosphere-derived cells 59 , where the cross-sectional area of cardiomyocytes in the infarcted border zone was 20% smaller when compared to those found in the untreated rats. Th ese results supported our model prediction that hypertrophy will regress in the borderzone's cardiomyocytes upon restoration of the LV contractility.
Th ere are a number of factors that could aff ect the outcome of cardiac regenerative therapies and so, could possibly explain the large disparity in outcome found in these studies. Th ese factors include the timing and methods of delivery, the optimal dosage and the recipient environment 62 . Little is known also about the myofi ber architecture and the intrinsic contractility of the regenerated tissue. Given that the ventricular wall mechanics is sensitive to the myofi ber architecture 63 , the structural arrangement of the regenerated cardiomyocytes would have an impact on the treatment outcome. Th e current model can be extended to investigate and optimize these treatment parameters.
CONCLUSION
In summary, we have demonstrated that the electromechanics-growth model can reproduce features found in clinical observations and animal experiments of MI and infarct regeneration. Th e ability of our model in reproducing the fi ndings from these studies also suggest, as with other in-vivo and in-vitro remodeling studies 37, 44, 45 , that the time-averaged myofi ber stretch is a probable stimuli for cardiomyocyte hypertrophy. Th is fi nding is signifi cant in a way because the local prescription of growth constitutive law (at the gauss points) can reproduce large-scale remodeling of the ventricular geometry (such as the LV cavity volume) that is qualitatively consistent with the physical observations. Of course, whether the time-averaged myofi ber stretch is the "true" hypertrophic stimuli can only be determined by testing the model with other pathologies (and treatments). In this aspect, the electromechanics-growth model is well set up for simulating heart diseases that involve long-term remodeling due to abnormalities in the excitation-contraction coupling mechanism and the associated treatments, e.g. cardiac resynchronization therapy for treatment of mechanical dyssynchrony due to left branch bundle block. We are currently pursuing research in this area.
Limitations
Th ere are a number of limitations associated with this model. First, we did not consider the eff ects of infarct expansion which can cause a thinning of the infarct 64 . Th is event can occurs early in the time course of MI remodeling.
Second, we did not take into account that the borderzone can extend itself during remodeling 48 . Although the borderzone in our simulation expands in size via cellular hypertrophy, this eff ect is diff erent from the extension of borderzone width when the adjacent healthy myocardium is progressively recruited into this dysfunctional zone.
Th ird, we did not take into account the immediate increase in LV wall volume aft er injection of new cells or retroviral particles that some of these cardiac therapies are based on. Although the injected volume is small compared to the LV wall volume in some studies (e.g., 2.5 mL injection vs. LV wall volume of ∼150 mL 60 ) , there are other studies in which the injected volume is signifi cant (e.g. 15 mL injection vs. LV wall volume of ∼50 mL 61 ). As shown in a number of modeling studies, the injection of new non-contractile materials into the LV wall can have an immediate impact on the regional mechanics that may aff ect the remodeling process 18, 65 . Last, the timescale associated with each growth cycle would need to be properly characterized based on longitudinal data acquired from animal models and patients. In this aspect, it is important to recognize the fact that the growth timescale will diff er across species, which have diff erent metabolism rates. For example, the growth timescale in a rat infarct model is likely to be less than that in a swine infarct model as suggested in the experiments, where cardiomyocytes at the infarct borderzone were found to be hypertrophied by 30% in 3 days in a rat model 66 and by 70% in 6 weeks in a swine model 67 . To account for interspecies diff erence in the growth timescale, it may be useful to characterize the timescale based on physiological time (as opposed to chronological time) using empirical allometric scaling relationships 68 . Moreover, experiments have also suggested a diff erent time scale for myocyte atrophy (reverse remodeling) from myocyte hypertrophy (remodeling) 35, 69 .
